There is no holding back Gilead Sciences’ (GILD – Analyst Report) hepatitis C virus (HCV) drug Sovaldi. The drug continued its exceptional performance in the second quarter of 2014, helping the company to beat the Consensus Estimate in Q2 on both revenues and earnings. The biopharmaceutical company’s second quarter adjusted earnings (including stock based compensation…
The Royal National Lifeboat Institution (RNLI), informally known as the UK’s fourth emergency service, has announced it is accepting bitcoin donations. The RNLI says it is the first major charity in the UK to accept bitcoin. It also happens to be one of the oldest charities in the country, as it was founded in 1824….
Google Inc (NASDAQ GOOG) wants to simplify your search experience. The search giant now lets users call businesses directly via Google+. Calls to businesses in the United States and Canada are free, calls to international businesses will require a small fee. You can now call a business directly from its Google Search listing. The fees…
In an unusual development, Facebook (NASDAQ FB) suffered from the biggest outage in its history on August 1. While connecting, Facebook displayed “Something Went Wrong” for almost 30 minutes. Similarly, you get a network error in the mobile apps and your content won’t refresh. The site went down for most users around 12 p.m. ET…
Up till now, Apple Inc. (NASDAQ:AAPL) was expected to launch its much-awaited iPhone 6 in September, but a new report suggests that fans might have to wait till October for their favorite device. Citing an internal Apple retail store meeting, a report from MacRumors claims that the next-generation iPhone will hit the markets on October…
Biogen Idec (BIIB) reported second quarter 2014 earnings per share of $3.48 (including the impact of stock-based compensation expense), way above the Consensus Estimate of $2.80 and the year-ago earnings of $2.29 per share. While oral multiple sclerosis (MS) drug, Tecfidera contributed significantly to revenues, the company also benefited from the approval of an agreement…
